<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Finerenone: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Finerenone: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Finerenone: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="132058" href="/d/html/132058.html" rel="external">see "Finerenone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F55992738"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Kerendia</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F57476146"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Kerendia</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F55960559"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Mineralocorticoid (Aldosterone) Receptor Antagonist;</li>
<li>
                        Nonsteroidal Mineralocorticoid (Aldosterone) Receptor Antagonist</li></ul></div>
<div class="block doa drugH1Div" id="F56014538"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Prior to initiating therapy, verify serum potassium ≤5 mEq/L; do not initiate therapy if serum potassium &gt;5 mEq/L. Patients with baseline serum potassium &gt;4.8 to 5 mEq/L were excluded from clinical trials; initiation in this group may be considered according to manufacturer’s labeling, but only with increased serum potassium monitoring during the first 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33264825','lexi-content-ref-34449181','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33264825','lexi-content-ref-34449181','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6c2ce5b5-97f7-442c-af65-5fb1b99b872b">Chronic kidney disease associated with type 2 diabetes</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic kidney disease associated with type 2 diabetes: Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used as an adjunctive agent for patients with persistently elevated urinary albumin excretion (urine albumin-to-creatinine ratio ≥30 mg/g) who are receiving other preferred therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.1','lexi-content-ref-36272764']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.1','lexi-content-ref-36272764'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Initial:</b></p>
<p style="text-indent:-2em;margin-left:6em;">eGFR ≥60 mL/minute/1.73 m<sup>2</sup>: 20 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR ≥25 to &lt;60 mL/minute/1.73 m<sup>2</sup>: 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR &lt;25 mL/minute/1.73 m<sup>2</sup>: Use not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance:</b> Maintenance dose is determined by serum potassium measured 4 weeks after initiation of therapy or a dose adjustment and periodically during therapy.</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption>
<b>Finerenone Maintenance Dose</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">
<b>Current serum potassium (mEq/L)</b></p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">
<b>Current finerenone dose</b></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>10 mg once daily</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>20 mg once daily</b></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;">
<sup>a </sup>If eGFR has decreased by &gt;30% compared to previous measurement, maintain 10 mg once daily dose.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">≤4.8</p></td>
<td align="center">
<p style="text-indent:0em;">Increase to 20 mg once daily.<sup>a</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Continue 20 mg once daily.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;4.8 to 5.5</p></td>
<td align="center">
<p style="text-indent:0em;">Continue 10 mg once daily.</p></td>
<td align="center">
<p style="text-indent:0em;">Continue 20 mg once daily.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;5.5</p></td>
<td align="center">
<p style="text-indent:0em;">Interrupt therapy. May consider restarting at 10 mg once daily when serum potassium ≤5 mEq/L.</p></td>
<td align="center">
<p style="text-indent:0em;">Interrupt therapy. Restart at 10 mg once daily when serum potassium ≤5 mEq/L.</p></td></tr></tbody></table></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Missed doses:</b> If a dose is missed, administer as soon as possible but only on the same day. If not possible, skip the dose and continue with the next dose as scheduled.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F56014540"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Prior to initiating therapy, verify serum potassium ≤5 mEq/L; do not initiate therapy if serum potassium &gt;5 mEq/L. Patients with baseline serum potassium &gt;4.8 to 5 mEq/L were excluded from clinical trials; initiation in this group may be considered according to the manufacturer’s labeling, but only with increased serum potassium monitoring during the first 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33264825','lexi-content-ref-34449181','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33264825','lexi-content-ref-34449181','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Initial:</b></p>
<p style="text-indent:-2em;margin-left:6em;">eGFR ≥60 mL/minute/1.73 m<sup>2</sup>: 20 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR ≥25 to &lt;60 mL/minute/1.73 m<sup>2</sup>: 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR &lt;25 mL/minute/1.73 m<sup>2</sup>: Use not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance:</b> Maintenance dose is determined by serum potassium measured 4 weeks after initiation of therapy or a dose adjustment and periodically during therapy.</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption>
<b>Finerenone Maintenance Dose</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">
<b>Current serum potassium (mEq/L)</b></p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">
<b>Current finerenone dose</b></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>10 mg once daily</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>20 mg once daily</b></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;">
<sup>a </sup>If eGFR has decreased by &gt;30% compared to previous measurement, maintain 10 mg once daily dose.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">≤4.8</p></td>
<td align="center">
<p style="text-indent:0em;">Increase to 20 mg once daily.<sup>a</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Continue 20 mg once daily.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;4.8 to 5.5</p></td>
<td align="center">
<p style="text-indent:0em;">Continue 10 mg once daily.</p></td>
<td align="center">
<p style="text-indent:0em;">Continue 20 mg once daily.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;5.5</p></td>
<td align="center">
<p style="text-indent:0em;">Interrupt therapy. May consider restarting at 10 mg once daily when serum potassium ≤5 mEq/L.</p></td>
<td align="center">
<p style="text-indent:0em;">Interrupt therapy. Restart at 10 mg once daily when serum potassium ≤5 mEq/L.</p></td></tr></tbody></table></div>
<div class="block doha drugH1Div" id="F56014541"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary; consider increased serum potassium monitoring in patients with moderate impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: (Child-Pugh class C): Avoid use.</p></div>
<div class="block doe drugH1Div" id="F56014539"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F56345538"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hyperkalemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia</b> was common in clinical trials; however, it resulted in permanent therapy discontinuation or hospitalization infrequently (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33198491','lexi-content-ref-34449181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33198491','lexi-content-ref-34449181'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Blocks aldosterone from binding to the mineralocorticoid receptor, resulting in sodium reabsorption while conserving potassium ions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23713082','lexi-content-ref-12937359']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23713082','lexi-content-ref-12937359'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; occurs within 4 weeks of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34449181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34449181'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Decreasing renal function. <b>Note: </b>Therapy initiation may cause an initial decrease in estimated GFR within the first 4 weeks and then stabilizes.</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher baseline potassium levels</p>
<p style="text-indent:-2em;margin-left:6em;">• Known risk factors for hyperkalemia (eg, proteinuria, diabetes)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant angiotensin-converting enzyme inhibitors, angiotensin-II receptor blockers, nonsteroidal anti-inflammatory drugs, and/or moderate CYP3A inhibitors</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F56014044"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Endocrine &amp; metabolic: Hyperkalemia (14%)<span class="lexi-table-link-container"> (<a aria-label="Hyperkalemia table link" class="lexi-table-link" data-table-id="lexi-content-hyperkalemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hyperkalemia')">table 1</a>)</span><span class="table-link" style="display:none;">Hyperkalemia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hyperkalemia" frame="border" id="lexi-content-hyperkalemia" rules="all">
<caption style="text-align:center;">
<b>Finerenone: Adverse Reaction: Hyperkalemia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Finerenone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Finerenone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6,510</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6,489</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyponatremia (1%)</p></div>
<div class="block coi drugH1Div" id="F55960561"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Concomitant treatment with strong CYP3A4 inhibitors; adrenal insufficiency.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Additional contraindications (not in US labeling): Hypersensitivity to finerenone or any component of the formulation; Addison disease.</p></div>
<div class="block war drugH1Div" id="F56014521"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Consider increased serum potassium monitoring in patients with moderate hepatic impairment; avoid use in patients with severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Dose adjustment may be required.</p></div>
<div class="block foc drugH1Div" id="F55992739"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kerendia: 10 mg, 20 mg</p></div>
<div class="block geq drugH1Div" id="F55992737"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F56136948"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Kerendia Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $26.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $26.36</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F57476147"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kerendia: 10 mg, 20 mg</p></div>
<div class="block adm drugH1Div" id="F56014542"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with or without food. If unable to swallow tablet whole, tablet may be crushed and mixed with water or soft foods (eg, applesauce); administer immediately after mixing.</p></div>
<div class="block use drugH1Div" id="F55960563"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Chronic kidney disease associated with type 2 diabetes:</b> To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes.</p></div>
<div class="block mst drugH1Div" id="F56235126"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Diuretics (finerenone) are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients ≥65 years of age due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F55986988"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C8 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F55986985"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aldesleukin: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: May enhance the hyperkalemic effect of Finerenone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: May enhance the hyperkalemic effect of Finerenone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Finerenone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Finerenone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Finerenone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Finerenone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Weak): May increase the serum concentration of Finerenone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elranatamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Epcoritamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fludrocortisone: May diminish the therapeutic effect of Mineralocorticoid (Aldosterone) Receptor Antagonists. Mineralocorticoid (Aldosterone) Receptor Antagonists may diminish the therapeutic effect of Fludrocortisone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glofitamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of Finerenone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mosunetuzumab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Salts: May enhance the hyperkalemic effect of Finerenone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of Finerenone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talquetamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teclistamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Treosulfan: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trofinetide: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F56014523"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Grapefruit juice increases finerenone concentrations. Management: Avoid concomitant use with grapefruit or grapefruit juice.</p></div>
<div class="block rep_considerations drugH1Div" id="F56014518"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">In the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) trial, patients who could become pregnant were required to have a negative pregnancy test prior to inclusion and use ≥2 effective methods of birth control (at least 1 being a physical barrier) during the study (Bakris 2020).</p></div>
<div class="block pri drugH1Div" id="F56014519"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Developmental toxicity was observed in animal reproduction studies with doses equivalent to ~4 times those expected in humans.</p></div>
<div class="block brc drugH1Div" id="F56014520"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if finerenone is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends that breastfeeding be avoided during therapy and for 1 day after the last finerenone dose.</p></div>
<div class="block mop drugH1Div" id="F56014544"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum potassium (at baseline, 4 weeks after initiation of therapy or dosage adjustments, and periodically during therapy with increased frequency in patients at risk for hyperkalemia); eGFR (at baseline and periodically during therapy).</p></div>
<div class="block pha drugH1Div" id="F56014525"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Finerenone selectively blocks mineralocorticoid receptor–mediated sodium reabsorption and overactivation in both epithelial (eg, kidney) and nonepithelial (eg, blood vessels, heart) tissues reducing fibrosis and inflammation.</p></div>
<div class="block phk drugH1Div" id="F56014526"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 52.6 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 92%; primarily to albumin.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily hepatic via CYP3A4 (90%) and to a lesser extent by CYP2C8 (10%) to inactive metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 44%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: 2 to 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 0.5 to 1.25 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~80%; &lt;1% as unchanged drug); feces (~20%; &lt;0.2% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F56014535"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: No clinically relevant differences in finerenone AUC or C<sub>max</sub> values in patients with eGFR 15 to &lt;90 mL/minute/1.73 m<sup>2</sup> compared to eGFR ≥90 mL/minute/1.73 m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: No clinically significant effect on AUC and C<sub>max</sub> in mild impairment (Child-Pugh class A). AUC increased by 38% and C<sub>max</sub> was unchanged in moderate impairment (Child-Pugh class B) compared to healthy control subjects.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58847490"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Kerendia</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finerenone-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.1">
<a name="ADA.1"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023. <i>Diabetes Care</i>. 2023;46(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed January 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33264825">
<a name="33264825"></a>Bakris GL, Agarwal R, Anker SD, et al; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. <i>N Engl J</i>
<i>Med</i>. 2020;383(23):2219-2229. doi:10.1056/NEJMoa2025845<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finerenone-drug-information/abstract-text/33264825/pubmed" id="33264825" target="_blank">33264825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33198491">
<a name="33198491"></a>Filippatos G, Anker SD, Agarwal R, et al. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. <i>Circulation</i>. 2021;143(6):540-552. doi:10.1161/CIRCULATIONAHA.120.051898<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finerenone-drug-information/abstract-text/33198491/pubmed" id="33198491" target="_blank">33198491</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kerendia (finerenone) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; September 2022.</div>
</li>
<li>
<div class="reference">
                  Kerendia (finerenone) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36272764">
<a name="36272764"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2022;102(5S):S1-S127. doi:10.1016/j.kint.2022.06.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finerenone-drug-information/abstract-text/36272764/pubmed" id="36272764" target="_blank">36272764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34449181">
<a name="34449181"></a>Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. <i>N Engl J Med</i>. 2021;10.1056/NEJMoa2110956. doi:10.1056/NEJMoa2110956<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finerenone-drug-information/abstract-text/34449181/pubmed" id="34449181" target="_blank">34449181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23713082">
<a name="23713082"></a>Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. <i>Eur Heart J</i>. 2013;34(31):2453-2463. doi:10.1093/eurheartj/eht187<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finerenone-drug-information/abstract-text/23713082/pubmed" id="23713082" target="_blank">23713082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12937359">
<a name="12937359"></a>Sica DA, Gehr TW, Yancy C. Hyperkalemia, congestive heart failure, and aldosterone receptor antagonism. <i>Congest Heart Fail</i>. 2003;9(4):224-229. doi:10.1111/j.1527-5299.2003.02397.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/finerenone-drug-information/abstract-text/12937359/pubmed" id="12937359" target="_blank">12937359</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 132042 Version 71.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
